Deutsche Bank Reiterates “Hold” Rating for CVS Health (CVS)

CVS Health (NYSE:CVS)‘s stock had its “hold” rating reissued by stock analysts at Deutsche Bank in a research report issued on Tuesday.

A number of other analysts also recently weighed in on CVS. Wolfe Research downgraded shares of CVS Health from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $89.00 to $82.00 in a report on Monday, August 14th. Robert W. Baird restated an “outperform” rating and issued a $90.00 target price on shares of CVS Health in a report on Monday, August 14th. Citigroup reduced their target price on shares of CVS Health from $88.00 to $87.00 and set a “neutral” rating on the stock in a report on Thursday, August 17th. Loop Capital initiated coverage on shares of CVS Health in a report on Thursday, August 24th. They issued a “hold” rating and a $83.00 target price on the stock. Finally, BidaskClub downgraded shares of CVS Health from a “hold” rating to a “sell” rating in a report on Friday, August 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $86.35.

Shares of CVS Health (NYSE:CVS) opened at $71.69 on Tuesday. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock has a market cap of $76,095.96, a price-to-earnings ratio of 13.16, a price-to-earnings-growth ratio of 1.29 and a beta of 0.89. CVS Health has a fifty-two week low of $66.45 and a fifty-two week high of $84.72.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.01. The company had revenue of $46.18 billion for the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. CVS Health’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.64 EPS. equities research analysts predict that CVS Health will post 5.9 earnings per share for the current year.

In related news, EVP Thomas M. Moriarty sold 90,267 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the transaction, the executive vice president now directly owns 70,102 shares in the company, valued at approximately $5,580,820.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David M. Denton sold 237,078 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the transaction, the chief financial officer now owns 141,096 shares in the company, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders have sold a total of 714,125 shares of company stock worth $58,119,381 over the last quarter. 0.61% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Fieldpoint Private Securities LLC lifted its position in shares of CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares during the period. Wealthcare Advisory Partners LLC lifted its position in shares of CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 991 shares during the period. Arcadia Investment Management Corp MI lifted its position in shares of CVS Health by 119.6% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in shares of CVS Health in the 2nd quarter worth approximately $119,000. Finally, Gemmer Asset Management LLC lifted its position in shares of CVS Health by 15.3% in the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after purchasing an additional 200 shares during the period. 82.24% of the stock is owned by institutional investors.

WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/05/deutsche-bank-reiterates-hold-rating-for-cvs-health-cvs.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply